As the ALS field progresses, marked by pivotal approvals and mounting investment into preclinical and clinical pipelines, the 3rd ALS Drug Development meeting returns as industry’s comprehensive guide to accelerate transformative treatments to patients faster.
What’s New for 2024?
Two dedicated tracks:
Bring your entire team to maximize the benefits of a wide range of content spanning discovery, preclinical, clinical, regulatory, and commercial discussions.
Brand-New Speakers:
Learn from a range of new representatives from the likes of Biogen, Takeda and NeuroSense as they share progress in genome editing, NfL-based detection of presymptomatic ALS, combination therapy regimens and more
Cutting-edge data readouts:
Discover the growing momentum in preclinical and clinical R&D as QurAlis, Coya Therapeutics, Sola Biosciences, BrainStorm Cell Therapeutics and more share recent breakthroughs
Novel patient insight:
As increasing numbers of therapies undergo investigation, understand how people living with ALS evaluate which trial to enrol in. Engage with ALS gene carriers and genetic counselors to collectively propel the advancement of comprehensive genetic testing
Extended Regulatory Discussions:
Hear first-hand experiences from AbbVie, Biogen and Mitsubishi Tanabe Pharma America and collaboratively navigate the evolving landscape of acceptable endpoints
Join Your Peers to:
Characterize expression of TDP-43 and C9orf72 among diverse forms of ALS. Look beyond TDP-43 to discover next-generation targets, with clinical updates on PIKfyve, STATHMIN-2, Tregs and more.
Build translational confidence of a truly sporadic iPSC model, leverage co-cultures to study cellular interactions in ALS, and overcome aggressive in vivo phenotypes caused by TDP-43 overexpression.
Modernize the clinical trial approach by incorporating DHTs, AI and digital biomarkers. Navigate hurdles of demonstrating efficacy on top of existing ALS therapies, while optimizing the potential of a combination approach.
Decipher the most meaningful endpoints to people living with ALS and evaluate the potential of novel surrogate biomarkers that extend beyond ALSFRS-R to monitor patients, enhancing dialogue with regulatory bodies about what these could be.
Explore novel biomarker opportunities to better understand ALS progression and detect sporadic ALS at the pre-symptomatic stage. Collaborate for earlier genetic testing to accelerate the onset of treatment for ALS gene carriers.
Who Will You Meet?
Hear From Last Year’s Attendees:
"Very relevant topics. Awesome and knowledgeable presenters. One of the best ALS meetings I have been to.”
Vice President Clinical Development, PTC Therapeutics
“The quality and expertise of the speakers was exceptional and the unique mix of academic and industry speakers in a collaboration also made it very valuable.”
Senior Director, Medical, Argenx
“This conference is an opportunity to learn about the latest in ALS drug development and network with peers.”
Head of Global Medical Affairs, Amylyx Pharmaceuticals
